Usefulness of bone turnover markers as predictors of mortality risk, disease progression and skeletal-related events appearance in patients with prostate cancer with bone metastases following treatment with zoledronic acid: TUGAMO study

British Journal of Cancer

Volumn 108, Issue 12, 2013, Pages 2565-2572

  De La Piedra, C ^a   Alcaraz, A ^b   Bellmunt, J ^c   Meseguer, C ^d   Gomez Caamano A ^e   Ribal, M J ^b   Vazquez F ^f   Anido, U ^e   Samper, P ^g   Esteban, E ^h   Alvarez Ossorio J L ⁱ   Lara, P C ^j   San Jose L A ^k   Contreras, J A ⁱ   Del Alba, A G ^l   Gonzalez Gragera B ^m   Tabernero, A J ⁿ   Gonzalez Enguita C ^o   Fernandez J M ^h   Garcia Escudero A ^p   Gomez Veiga F ^q   Mendez M J ^r   Segarra, J ^s   Virizuela, J A ^t   Carles, J ^u   Lassa, A ^v   Calderero, V ^w   Constela, M ^x   Delgado, D ^y   Manas A ⁿ   Murias, A ^z   Reynes, G ^aa   Rodriguez, B ^ab   Rubio, G ^o   Sanchez E ^t   Unda, M ^ac   Solsona, E ^ad   Martinez Javaloyas J M ^ae   Comet Batlle, J ^af   Quicios, C ^o   Martin Fernandez M ^a   Mahillo Fernandez I ^a   Morote, J ^u   more..

^a INSTITUTO DE INVESTIGACIÓN SANITARIA DEL HOSPITAL CLÍNICO SAN CARLOS IDISSC   (Spain)

^b HOSPITAL CLÍNIC   (Spain)

^c HOSPITAL DEL MAR   (Spain)

^d Medical Affairs Department   (Spain)

^e HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

^f HOSPITAL UNIVERSITARIO VIRGEN DE LAS NIEVES   (Spain)

^g HOSPITAL CENTRAL DE LA DEFENSA GÓMEZ ULLA   (Spain)

^h HOSPITAL UNIVERSITARIO CENTRAL DE ASTURIAS   (Spain)

ⁱ HOSPITAL UNIVERSITARIO PUERTA DEL MAR   (Spain)

^j HOSPITAL UNIVERSITARIO DE GRAN CANARIA DR NEGRÍN   (Spain)

^k HOSPITAL CLÍNICO SAN CARLOS   (Spain)

^l HOSPITAL UNIVERSITARIO SON ESPASES   (Spain)

^m HOSPITAL SON LLÀTZER   (Spain)

ⁿ HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^o Hospital UniversitarioFundación Jiménez Díaz   (Spain)

^p HOSPITAL TXAGORRITXU   (Spain)

^q HOSPITAL JUAN CANALEJO   (Spain)

^r HOSPITAL UNIVERSITARIO REINA SOFÍA   (Spain)

^s HOSPITAL UNIVERSITARI JOAN XXIII   (Spain)

^t HOSPITAL UNIVERSITARIO VIRGEN MACARENA   (Spain)

^u HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^v Hospital Ernest Lluch Martin   (Spain)

^w HOSPITAL UNIVERSITARIO MIGUEL SERVET   (Spain)

^x HOSPITAL MONTECELO   (Spain)

^y HOSPITAL UNIVERSITARIO NUESTRA SEÑORA DE CANDELARIA   (Spain)

^z HOSPITAL UNIVERSITARIO INSULAR DE GRAN CANARIA   (Spain)

^aa HOSPITAL UNIVERSITARIO LA FE   (Spain)

^ab Servicio de Urología   (Spain)

^ac HOSPITAL DE BASURTO   (Spain)

^ad INSTITUTO VALENCIANO DE ONCOLOGÍA   (Spain)

^ae HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

^af HOSPITAL JOSEP TRUETA   (Spain)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALKALINE PHOSPHATASE; CARBOXY TERMINAL TELOPEPTIDE; COLLAGEN TYPE 1; PROCOLLAGEN; ZOLEDRONIC ACID;

ADULT; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; BONE METASTASIS; BONE TURNOVER; CANCER GROWTH; CANCER HORMONE THERAPY; CANCER MORTALITY; CANCER SURVIVAL; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTICENTER STUDY; OBSERVATIONAL STUDY; PREDICTIVE VALUE; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROSTATE CANCER; PROTEIN BLOOD LEVEL; SURVIVAL TIME; TREATMENT DURATION;

AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; BONE DENSITY CONSERVATION AGENTS; BONE NEOPLASMS; BONE REMODELING; DIPHOSPHONATES; DISEASE PROGRESSION; FOLLOW-UP STUDIES; HUMANS; IMIDAZOLES; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROSTATIC NEOPLASMS; RISK FACTORS; SURVIVAL ANALYSIS;

EID: 84879685770     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2013.270     Document Type: Article

References (23)

1. Bickers B, Aukhim-Hasie C (2009) New molecular biomarkers for the prognosis and management of prostate cancer. The post PSA era. Anticancer Res 29: 3289-3298.
2. Brasso K, Christensen IJ, Johansen JS, Teisner B, Garnero P, Price PA, Iversen P (2006) Prognostic value of PINP, bone alkaline phosphatase, CTX-I, and YKL-40 in patients with metastatic prostate carcinoma. Prostate 66: 503-513.
3. Buijs JT, Pluijm G (2009) Osteotropic cancers: from primary tumor to bone. Cancer Lett 273: 177-193.
4. Coleman RE (1997) Skeletal complications of malignancy. Cancer 80: 1588-1594.
5. Coleman RE, Lipton A, Roodman GD, Guise TA, Boyce BF, Brufsky AM, Clézardin P, Croucher PI, Gralow JR, Hadji P, Holen I, Mundy GR, Smith MR, Suva LJ (2010) Metastasis and bone loss: advancing treatment and prevention. Cancer Treat Rev 36: 615-620.
6. Cook GJR, Fogelman I (2000) Diagnosis and monitoring on bone metastases: scintigraphy. In Tumor bone diseases and osteporosis in cancer patients, Body JJ (ed) pp 131-154. Marcel Dekker: New York.
7. De la Piedra C, Castro-Errecaborde NA, Traba ML, Méndez- Dávila C, García Moreno C, Rodriguez de Acuña L, Rodriguez Molina J (2003) Bone remodeling markers in the detection of bone metastases in prostate cancer. Clin Chim Acta 331: 45-53.
8. Garnero P, Delmas PD (1993) Assessment of the serum levels of bone alkaline phosphatase with a new immunoradiometric assay in patients with metabolic bone disease. J Clin Endocrin Metab 77: 1046-1053.
9. Huang Q, Ouyang X (2012) Biochemicals-markers for the diagnosis of bone metastasis: A clinical review. Cancer Epidemiology 36: 94-98.
10. Jung K, Miller K, Wirth M, Albrech M, Lein M (2011) Bone turnover markers as predictors of mortality risk in prostate cancer patients with bone metastases following treatment with zoledronic acid. Eur Urol 59: 604-612.
11. Leeming DJ, Koizumi M, Byrjalsen I, Li B, Qvist P, Tankó LB (2006) The relative use of eight collagenous and noncollagenous markers for diagnosis of skeletal metastases in breast, prostate or lung cancer. Cancer Epidemiol Biomarkers Prev 15: 32-28.
12. Lein M, Wirth M, Miller K, Eickenberg HU, Weissbach L, Schmidt K, Haus U, Stephan C, Meissner S, Loening SA, Jung K (2007) Serial markers of bone turnover in men with metastatic prostate cancer treated with zoledronic acid for detection of bone metastases progression. Eur Urol 52: 1381-1387.
13. Lein M, Miller K, Wirth M, Weissbach L, May C, Schmidt K, Haus U, Schrader M, Jung K (2009) Bone turnover markers as predictive tools for skeletal complications in men with metastatic prostate cancer treated with zoledronic acid. Prostate 69: 624-632.
14. Lipton A, Cook RJ, Major P, Smith MR, Coleman RE (2007) Zoledronic acid and survival in breast cancer patients with bone metastases and elevated markers of osteoclast activity. Oncologist 12: 1035-1043.
15. Lorente JA, Morote J, Raventos C, Encabo G, Valenzuela H (1996) Clinical efficacy of bone alkaline phosphtase and prostate specific antigen in the diagnosis of bone metastases in prostate cancer. J Urol 155: 1348-1351.
16. Mountzios G, Terpos E, Syrigos K, Papadimitriou C, Papadopoulos G, Bamias A, Mavrikakis M, Dimopoulos MA (2010) Markers of bone remodeling and skeletal morbidity in patients with solid tumors metastatic to the skeleton receiving the bisphosphonates zoledronic acid. Transl Res 155: 247-255.
17. Mundy GR (2002) Metastases to bone: causes, consequences and therapeutic opportunities. Nat Rev Cancer 2: 584-593.
18. Polascik TJ, Mouraviev V (2008) Zoledronic acid in the management of metastatic bone disease. Ther Clin Risk Manag 4: 261-268.
19. Santini D, Vicenzi B, Hannon RA, Brown JE, Dicuonzo G, Angeletti S, La Cesa A, Coleman RE, Tonini G, Budillon A, Caraglia M, Holen I (2006) Changes in bone resorption and vascular endothelial growth factor after a single zoledronic acid infusion in cancer patients with bone metastases from solid tumours. Oncol Rep 15: 1351-1357.
20. Shariat SF, Canto EI, Kattan MW, Slawin KM (2004) Beyond prostate-specific antigen: new serologic biomarkers for improved diagnosis and management of prostate cancer. Rev Urol 6: 58-72.
21. Smith MR, Goode MJ, Zietman AL, McGovern FJ, Lee H, Finkelstein JS (2004) Bicalutamide monothetapy versus leuprolide monotherapy for prostate cancer: effects on bone mineral density and body composition. J Clin Oncol 22: 2546-2553.
22. Soloway MS, Hardeman SW, Hickey D, Raymond J, Todd B, Soloway S, Moinuddin M (1998) Stratification of patients with prostate cancer based on extent of disease on initial bone scan. Cancer 61: 195-202.
23. Vasikaran S, Eastell R, Bruyère O, Foldes AJ, Garnero P, Griesmacher A, McClung M, Morris HA, Silverman S, Trenti T, Wahl DA, Cooper C, Kanis JA. IOF-IFCC Bone Marker Standards Working Group (2011) Markers of bone turnover for the prediction of fracture risk and monitoring of osteoporosis treatmen: a need for internatoional reference standards. Osteoporosis Int 22: 391-420.